Skip to main content

Table 1 Baseline characteristics by ELN 2017 risk subgroup

From: Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

 

Intermediate-risk AML

 

Adverse-risk AML

 
 

CPX-351 (n = 40)

7 + 3 (n = 41)

CPX-351 (n = 99)

7 + 3 (n = 100)

Median age (range), years

69 (61, 75)

68 (60, 75)

68 (60, 75)

68 (60, 75)

Age subgroup, n (%)

    

 60 to 69 years

25 (63)

26 (63)

62 (63)

65 (65)

 70 to 75 years

15 (38)

15 (37)

37 (37)

35 (35)

Male, n (%)

29 (73)

25 (61)

57 (58)

63 (63)

ECOG performance status, n (%)

    

 0

11 (28)

14 (34)

20 (20)

29 (29)

 1

25 (63)

23 (56)

70 (71)

57 (57)

 2

4 (10)

4 (10)

9 (9)

14 (14)

AML subtype, n (%)

    

 t-AML

9 (23)

3 (7)

17 (17)

27 (27)

 AML with antecedent MDS

    

  With prior HMAs

19 (48)

19 (46)

29 (29)

32 (32)

  Without prior HMAs

6 (15)

12 (29)

12 (12)

6 (6)

 AML with antecedent CMML

2 (5)

4 (10)

7 (7)

6 (6)

 de novo AML with MDS karyotype

4 (10)

3 (7)

34 (34)

29 (29)

NCCN cytogenetic risk, n (%)

    

 n

39

37

92

97

 Better risk

0

1 (3)

0

0

 Intermediate risk

31 (79)

31 (84)

30 (33)

26 (27)

 Poor risk

8 (21)

5 (14)

62 (67)

71 (73)

TP53 mutation, n (%)

24 (24)

31 (31)

WBC count, n (%)

    

 n

40

40

99

100

  < 20,000/µL

33 (83)

35 (88)

87 (88)

83 (83)

  ≥ 20,000/µL

7 (18)

5 (13)

12 (12)

17 (17)

Platelet count, n (%)

    

 n

40

40

99

99

  ≤ 50,000/µL

20 (50)

21 (53)

66 (67)

62 (63)

  > 50,000/µL

20 (50)

19 (48)

33 (33)

37 (37)

Median bone marrow blasts (range)a, %

36 (5, 80)

35 (6, 88)

35 (5, 93)

35 (3, 97)

Bone marrow blasts, n (%)

    

 n

38

40

97

97

  < 20%

5 (13)

4 (10)

15 (15)

18 (19)

 20% to 40%

14 (37)

19 (48)

42 (43)

41 (42)

  > 40% to 60%

10 (26)

10 (25)

20 (21)

18 (19)

  > 60%

9 (24)

7 (18)

20 (21)

20 (21)

  1. AML acute myeloid leukemia; CMML chronic myelomonocytic leukemia; ECOG Eastern Cooperative Oncology Group; ELN European LeukemiaNet; HMA hypomethylating agent; MDS myelodysplastic syndrome; NCCN National Comprehensive Cancer Network; t-AML therapy-related acute myeloid leukemia; WBC white blood cell
  2. aData available for 34 and 37 patients in the CPX-351 and 7 + 3 arms, respectively, within the intermediate-risk subgroup and 93 and 91 patients within the adverse-risk subgroup